Advertisement

Japanese Journal of Ophthalmology

, Volume 62, Issue 2, pp 137–143 | Cite as

A 5-year multicenter prospective cohort study on the long-term visual prognosis and predictive factors for visual outcome in Japanese patients with age-related macular degeneration: the AMD2000 study

  • Yumiko Akagi-Kurashige
  • Akitaka TsujikawaEmail author
  • Mitsuko Yuzawa
  • Tatsuro Ishibashi
  • Hideo Nakanishi
  • Eiji Nakatani
  • Satoshi Teramukai
  • Masanori Fukushima
  • Nagahisa Yoshimura
  • AMD2000 study group
Clinical Investigation
  • 439 Downloads

Abstract

Purpose

In this study (AMD2000), we aimed to determine the visual prognosis of Japanese patients with age-related macular degeneration (AMD).

Methods

This was a multicenter prospective observational cohort study. In total, 460 patients with AMD were recruited from April 2006 to March 2009 from 18 clinical trial sites in Japan. They were followed up for 5 years, as they continued to receive medical treatment.

Results

Of the 409 study eyes followed up for at least 1 year, 243 eyes (59.4%) were treated with photodynamic therapy (PDT) using verteporfin, and 58 eyes (14.2%) were treated with intravitreal injections of antivascular endothelial growth factor agents as the initial treatment. The mean best-corrected visual acuities (BCVA) for typical AMD (tAMD; 0.688 ± 0.498) and polypoidal choroidal vasculopathy (PCV; 0.451 ± 0.395) were significantly less at 2 years (tAMD, 0.779 ± 0.632, P < 0.05; PCV, 0.534 ± 0.618, P < 0.05) and at 5 years (AMD, 0.873 ± 0.718, P < 0.05; PCV, 0.635 ± 0.668, P < 0.05) than at baseline. In eyes with tAMD, absence of blocked fluorescence was associated with 5-year maintenance of the baseline BCVA. Regarding PCV, the presence of polypoidal lesions and cystoid macular edema as well as the lesion size was associated with 5-year maintenance of the baseline BCVA. In some patients, the diagnosis changed: of the 192 eyes initially diagnosed with typical AMD, 19 were newly diagnosed with PCV during follow-up.

Conclusion

Maintaining the baseline BCVA over the long term is difficult in Japanese eyes with wet AMD.

Keywords

Age-related macular degeneration Photodynamic therapy Polypoidal choroidal vasculopathy Prospective study Visual prognosis 

Notes

Acknowledgements

We are grateful to all patients and coinvestigators for their cooperation for the current study. Principal investigator Nagahisa Yoshimura (Kyoto University Hospital). Co-principal investigator Tatsuro Ishibashi (Kyushu University Hospital) and Mitsuko Yuzawa (Surugadai Nihon University Hospital). Research sites and investigators Sapporo City General Hospital, Hokkaido (Muneyasu Takeda, Hiroko Imaizumi, Utako Okushiba); Hirosaki University Hospital, Aomori (Mitsuru Nakazawa, Yukihiko Suzuki); Yamagata University Hospital, Yamagata (Hidetoshi Yamashita, Daijiro Tsuchiya); Gunma University Hospital, Gunma (Shoji Kishi, Ryo Mukai, Maki Takahashi, Taku Sato, Hidetaka Matsumoto); Tokyo Medical University Ibaraki Medical Center, Ibaraki (Masahiro Miura); Surugadai Nihon University Hospital, Tokyo (Mitsuko Yuzawa, Ryuzaburo Mori); Tokyo University Hospital, Tokyo (Yasuhiro Tamaki, Ryo Obata, Yasuo Yanagi); Tokyo Medical University Hospital, Tokyo (Takuya Iwasaki, Yasuyuki Yamauchi); Yokohama City University Medical Center, Kanagawa (Kazuaki Kadonosono, Maiko Inoue, Misa Suzuki); Seirei Hamamatsu General Hospital, Shizuoka (Akira Obana); Fujita Health University Hospital, Aichi (Masayuki Horiguchi, Atsuhiro Tanikawa); Kyoto University Hospital, Kyoto (Nagahisa Yoshimura, Akitaka Tsujikawa, Hideo Nakanishi, Yumiko Akagi-Kurashige, Kenji Yamashiro, Atsushi Otani, Hiroshi Tamura, Ayako Takahashi, Akio Oishi); Osaka University Hospital, Osaka (Fumi Gomi, Miki Sawa); Osaka Medical College Hospital, Osaka (Tsunehiko Ikeda, Masahiro Minami); Kansai Medical University Hospital, Osaka (Kanji Takahashi); Kansai Medical University Takii Hospital, Osaka (Kenichiro Sho); Kobe University Hospital, Hyogo (Shigeru Honda); Kagoshima University Medical and Dental Hospital, Kagoshima (Taiji Sakamoto, Akiko Okubo). The authors also thank the following additional investigators of the Translational Research Informatics Center for their contributions to this trial: Emiko Uno for data management; Yasuko Kimura for project management; and Hideaki Kaneda, Mikio Yoshidomi, Shinsuke Kojima, and Atsuhiko Kawamoto for manuscript review.

Conflicts of interest

Y. Akagi-Kurashige, None; A. Tsujikawa, Grant (Alcon, AMO Japan, Bayer, HOYA, Kowa, Novartis, Pfizer, Santen, Senju), Lecture fees, (Alcon, AMO Japan, Bayer, Chugai, Kowa, Nidek, Novartis, Pfizer, Santen, Sanwa Kagaku, Senju); M. Yuzawa, Grant (Alcon Japan, Santen), Consultant fees (Alcon Japan, Astellas Pharma, Janssen Japan), Lecture fees (Astellas Pharma, Bausch & Lomb Japan, Bayer, Japan Focus Company, Novartis, Santen, Senju); T. Ishibashi, None; H. Nakanishi, None; E. Nakatani, None; S. Teramukai, Grant (Daiichi Sankyo), Consultant fee (Daiichi Sankyo, Sanofi, Solasia Pharma, Sysmex, Taiho Pharmaceutical), Lecture fees (Bristol-Myers Squibb, Fujifilm); M. Fukushima, None; N. Yoshimura, None.

References

  1. 1.
    Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106–16.CrossRefPubMedGoogle Scholar
  2. 2.
    Danis RP, Lavine JA, Domalpally A. Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects. Clin Ophthalmol. 2015;9:2159–74.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Wong CW, Yanagi Y, Lee WK, Ogura Y, Yeo I, Wong TY, et al. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res. 2016;53:107–39.CrossRefPubMedGoogle Scholar
  4. 4.
    Oishi A, Tsujikawa A, Yamashiro K, Ooto S, Tamura H, Nakanishi H, et al. One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome. Am J Ophthalmol. 2015;159(853–60):e1.Google Scholar
  5. 5.
    Saito M, Kano M, Itagaki K, Sekiryu T. Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration. Jpn J Ophthalmol. 2017;61:74–83.CrossRefPubMedGoogle Scholar
  6. 6.
    Hosokawa M, Morizane Y, Hirano M, Kimura S, Kumase F, Shiode Y, et al. One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2017;61:150–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration: the International ARM Epidemiological Study Group. Surv Ophthalmol. 1995;39:367–74.CrossRefPubMedGoogle Scholar
  8. 8.
    Zhang J, Yu Z, Liu L. Multimodality imaging in diagnosing polypoidal choroidal vasculopathy. Optom Vis Sci. 2015;92:e21–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Semoun O, Coscas F, Coscas G, Lalloum F, Srour M, Souied EH. En face enhanced depth imaging optical coherence tomography of polypoidal choroidal vasculopathy. Br J Ophthalmol. 2016;100:1028–34.CrossRefPubMedGoogle Scholar
  10. 10.
    Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10:1–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Iijima H, Imai M, Gohdo T, Tsukahara S. Optical coherence tomography of idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol. 1999;127:301–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Sato T, Kishi S, Watanabe G, Matsumoto H, Mukai R. Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy. Retina. 2007;27:589–94.CrossRefPubMedGoogle Scholar
  13. 13.
    Japanese age-related macular degeneration trial. 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol. 2003;136:1049–61.CrossRefGoogle Scholar
  14. 14.
    Tano Y. Pegaptanib Sodium Multi-center Study, G. Pegaptanib sodium one-year treatment study for neovascular age-related macular degeneration [in Japanese]. Nippon Ganka Gakkai Zasshi. 2008;112:590–600.PubMedGoogle Scholar
  15. 15.
    Japanese Study Group of Polypoidal Choroidal Vasculopathy. Criteria for diagnosis of polypoidal choroidal vasculopathy [in Japanese]. Nippon Ganka Gakkai Zasshi. 2005;109:417–27.Google Scholar
  16. 16.
    Yannuzzi LA, Negrao S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina. 2001;21:416–34.CrossRefPubMedGoogle Scholar
  17. 17.
    Hirami Y, Mandai M, Takahashi M, Teramukai S, Tada H, Yoshimura N. Association of clinical characteristics with disease subtypes, initial visual acuity, and visual prognosis in neovascular age-related macular degeneration. Jpn J Ophthalmol. 2009;53:396–407.CrossRefPubMedGoogle Scholar
  18. 18.
    Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report. Arch Ophthalmol. 1999;117:1329–45.CrossRefGoogle Scholar
  19. 19.
    Group VISiONCT, Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006;113:1508(e1–25).Google Scholar
  20. 20.
    Newman DK. Photodynamic therapy: current role in the treatment of chorioretinal conditions. Eye (Lond). 2016;30:202–10.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology. 2008;115:141–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Otani A, Sasahara M, Yodoi Y, Aikawa H, Tamura H, Tsujikawa A, et al. Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2007;144:7–14.CrossRefPubMedGoogle Scholar
  23. 23.
    Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32:1453–64.CrossRefPubMedGoogle Scholar
  24. 24.
    Koh A, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 2017;135:1206–13.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kikushima W, Sakurada Y, Sugiyama A, Tanabe N, Yoneyama S, Iijima H. Retreatment of polypoidal choroidal vasculopathy after photodynamic therapy combined with intravitreal ranibizumab. Jpn J Ophthalmol. 2017;61:61–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119:1175–83.CrossRefPubMedGoogle Scholar
  27. 27.
    Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Kurashige Y, Otani A, Sasahara M, Yodoi Y, Tamura H, Tsujikawa A, et al. Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2008;146:513–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Akaza E, Mori R, Yuzawa M. Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. Retina. 2008;28:717–22.CrossRefPubMedGoogle Scholar
  30. 30.
    Tsujikawa A, Ojima Y, Yamashiro K, Nakata I, Ooto S, Tamura H, et al. Association of lesion size and visual prognosis to polypoidal choroidal vasculopathy. Am J Ophthalmol. 2011;151(961–72):e1.Google Scholar
  31. 31.
    Tsujikawa A, Ojima Y, Yamashiro K, Ooto S, Tamura H, Nakata I, et al. Development of polypoidal lesions in age-related macular degeneration. Eye (Lond). 2011;25:481–8.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Imamura Y, Engelbert M, Iida T, Freund KB, Yannuzzi LA. Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol. 2010;55:501–15.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Ophthalmological Society 2017

Authors and Affiliations

  • Yumiko Akagi-Kurashige
    • 1
  • Akitaka Tsujikawa
    • 1
    • 6
    Email author
  • Mitsuko Yuzawa
    • 2
  • Tatsuro Ishibashi
    • 3
  • Hideo Nakanishi
    • 1
  • Eiji Nakatani
    • 4
  • Satoshi Teramukai
    • 4
    • 5
  • Masanori Fukushima
    • 4
  • Nagahisa Yoshimura
    • 1
  • AMD2000 study group
  1. 1.Department of Ophthalmology and Visual SciencesKyoto University Graduate School of MedicineKyotoJapan
  2. 2.Division of Ophthalmology, Department of Visual SciencesNihon University School of MedicineTokyoJapan
  3. 3.Department of Ophthalmology, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan
  4. 4.Translational Research Informatics CenterFoundation for Biomedical Research and InnovationKobeJapan
  5. 5.Department of Biostatistics, Graduate School of Medical ScienceKyoto Prefectural University of MedicineKyotoJapan
  6. 6.Department of OphthalmologyKyoto University Graduate School of MedicineKyotoJapan

Personalised recommendations